FDA Hands Warning Letter to STI Pharma for Adverse Events Reporting By Sam | January 17, 2017 The FDA issued a warning letter to STI Pharma for serious violations of adverse event reporting requirements. Source: Drug GMP Report Posted in Drug GMP Report